G1 Therapeutics To Present At The 18th Annual BIO CEO & Investor Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 18th Annual BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 9 at 1:30 p.m. ET at the Waldorf Astoria New York in New York City.

For additional information on the conference, visit: http://www.bio.org/events/conferences/bio-ceo-investor-conference.

About G1 Therapeutics, Inc.

G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.

Visit www.g1therapeutics.com for more information.

Contact:                                                                Mark Velleca, MD, PhD                 G1 Therapeutics                                               919-213-9838                                                     mvelleca@g1therapeutics.com                  Media: Laura Bagby                      6 Degrees Communications 312-448-8098 lbagby@6degreespr.com